Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
Source: Computational Materials Science, Volume 266
。91视频对此有专业解读
* Subscribers only
Re: Mandatory Developer Registration for Android App Distribution